Protocol Ledger

NCT06700499 · Phase II · COMPLETED

A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Interventional Phase II clinical trial protocol NCT06700499 sponsored by Akeso in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-08 Enrollment: 450 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06700499
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)450 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06700499
Protocol FieldVerified Registry Value
NCT IdentifierNCT06700499
Consolidated Lead SponsorAkeso
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment450 participants (ACTUAL)
Registered Start Date2024-07-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI